Drugs / CTX110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04035434 | Jul 2019 → Oct 2024 | B-cell adult acute lymphocytic leukemia | CRISPR Therapeutics AG | Terminated | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2022-12-12 | CRISPR Therapeutics | Results CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110® crisprtx.com ↗
Emerging data from Part B demonstrate the benefits of consolidation dosing with a positively differentiated safety profile consistent with Part A- |
| 2021-11-22 | CRISPR Therapeutics | Regulatory CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies crisprtx.com ↗
today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. |
| 2021-11-03 | CRISPR Therapeutics | Results CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results crisprtx.com ↗
Reported positive results from the ongoing Phase 1 CARBON clinical trial evaluating the safety and efficacy of CTX110 for CD19+ B-cell malignancies |
| 2021-10-12 | CRISPR Therapeutics | Results CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies crisprtx.com ↗ |
| 2020-10-21 | CRISPR Therapeutics | Results CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies crisprtx.com ↗
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04035434 ↗ |
| Modality | Cell therapy | “CTX110 is a CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of B cell malignancies.” NCT04035434 ↗ |
| Route | Intravenous | “Administered by IV infusion following lymphodepleting chemotherapy.” NCT04035434 ↗ |
| Target | CD19 | “CTX110 is a CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy” NCT04035434 ↗ |